N@N

Natus Medical Receives $2.7 Million Order for Newborn Care Products

^{Published on 2010-07-27 04:12:00 - Market Wire}
 

SAN CARLOS, Calif.--([ BUSINESS WIRE ])--Natus Medical Incorporated (Nasdaq:BABY) today announced that it has received a significant purchase order from the Kingdom of Saudi Arabia for the Companya™s newborn care products.

"The significant commitment to our combination Cool-Cap and CFM technology is also a very positive development in establishing selective head cooling as a standard of care outside of the United States for the treatment of hypoxic ischemic encephalopathy."

The order, which is valued at over $2.7 million, was received from the Companya™s distribution partner working with the Saudi Ministry of Health. The order is for ALGO newborn hearing screeners, Cool-Cap selective head-cooling devices, and Olympic Cerebral Function Monitors (CFM). The order is expected to ship by the end of the year.

aI am very pleased that this purchase of a large quantity of our ALGO newborn hearing screeners will result in many more babies being screened for hearing loss at birth,a said Jim Hawkins, President and Chief Executive Officer of the Company. aThe significant commitment to our combination Cool-Cap and CFM technology is also a very positive development in establishing selective head cooling as a standard of care outside of the United States for the treatment of hypoxic ischemic encephalopathy.a

aIn June we also shipped a $1.6 million order directly to the Iraq Ministry of Health for our neoBLUE phototherapy devices and disposable supplies,a Hawkins added. aWe are very pleased to see Ministries of Health putting such a strong emphasis on newborn care. We are hopeful this will continue throughout the region.a

ALGO screeners are the recognized gold standard in newborn hearing screening with clinically proven and well documented sensitivity and specificity. ALGO screeners incorporate Automated Auditory Brainstem Response (AABR) technology that screens the entire hearing pathway and has been validated in over 100 peer-reviewed clinical studies. The Olympic CFM is used in the neonatal intensive care unit (NICU) and other acute care departments within the hospital to continuously monitor an infant's brain activity, enabling clinical staff to assess the neurological status of the brain as an aid to both diagnosis and treatment. The Olympic Cool-Cap system provides selective head cooling to prevent or reduce the severity of neurologic injury associated with hypoxic ischemic encephalopathy (HIE) in newborns.

Financial Results Conference Call

In a press release issued on July 22, 2010 Natus announced that it intends to release its 2010 second quarter financial results before the market opens on Thursday, July 29, 2010. Natus management will host an investment-community conference call the same day beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) to discuss those results and to answer questions.

Individuals interested in listening to the conference call may do so by dialing 866-314-4865 for domestic callers, or 1-617-213-8050 for international callers, and entering reservation code 10066240. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 888-286-8010 for domestic callers, or 1-617-801-6888 for international callers, and entering reservation code 41276438.

The conference call also will be available real-time via the Internet at [ http://investor.natus.com ], and a recording of the call will be available on the Company's Web site for 90 days following the completion of the call.

About Natus Medical

Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories.

ALGO, AABR, and Cool-Cap are registered trademarks of Natus Medical Incorporated.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include, but are not limited to, statements regarding the anticipated shipping date of a recent order. These statements relate to current estimates and assumptions of our management as of the date of this press release, and future events or Natus' future financial performance or results involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Natus' future results could differ materially from those expressed or implied by the forward-looking statements due to a number of factors, including the ability to produce and ship products in a timely manner. Natus disclaims any obligation to update information contained in any forward looking statement.

More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2009, and its quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.

Additional information about Natus Medical can be found at [ www.natus.com ].